Foster City, CA, United States of America

Felipe Acosta Archila

USPTO Granted Patents = 1 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Felipe Acosta Archila: Innovator in Transplant Medicine

Introduction

Felipe Acosta Archila is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of transplant medicine through his innovative research and patent work. His expertise lies in the detection of donor-derived cell-free DNA, which is crucial for monitoring the status of allografts in transplant recipients.

Latest Patents

Felipe holds a patent titled "Methods for detection of donor-derived cell-free DNA." This patent provides methods for determining the status of an allograft within a transplant recipient from genotypic data measured from a mixed sample of DNA. The mixed sample comprises DNA from both the transplant recipient and the donor. The methods described in the patent aim to minimize allelic bias by preferentially enriching the mixed sample at a plurality of polymorphic loci, utilizing techniques such as massively multiplexed targeted PCR. He has 1 patent to his name.

Career Highlights

Felipe Acosta Archila is currently employed at Natera, Inc., a company known for its advancements in genetic testing and diagnostics. His work at Natera focuses on improving transplant outcomes through innovative genetic methodologies. His contributions have been instrumental in enhancing the understanding of allograft status and patient care.

Collaborations

Felipe has collaborated with esteemed colleagues such as Solomon Moshkevich and Bernhard Zimmermann. These collaborations have fostered a productive environment for research and innovation in the field of transplant medicine.

Conclusion

Felipe Acosta Archila is a pioneering inventor whose work in the detection of donor-derived cell-free DNA has the potential to transform transplant medicine. His contributions continue to impact patient care and improve outcomes in transplant procedures.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…